



Astec LifeSciences Ltd.

Dated: 23rd October, 2013

To,
The Department of Corporate Services
National Stock Exchange Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra, Mumbai-400051

Ref: "ASTEC"

Sub: Outcome of Board Meeting

Dear Sir,

This is to inform you that the Board of Directors at their meeting held on 23rd October, 2013 has:

- 1) Approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended 30.09.2013. (enclosed herewith)
- 2) Half Yearly Assets & Liabilities Statement as of 30.09.2013 (enclosed herewith).
- 3) Approved the Limited Review Report on Unaudited Financial Results for the quarter ended 30.09.2013. (enclosed herewith)

Please take the same on your records.

Thanking you,

Yours Sincerely,

FOR ASTEC LIFESCIENCES LIMITED

Tejal Jariwala
Company Secretary & Compliance Officer



Encl: as above



ISO 9001:2008



ISO 14001:2004



OHSAS 18001:2007

Head Office :
Elite Square, 7th Floor,
274, Perin Nariman Street,
Fort, Mumbai - 400001, India
Phone : +91-22- 2261 8212/ 6120 5600
Fax : +91-22- 2261 8289
E-mail : ah@astecsl.com
Website : www.astecsl.com

Unaudited Financial Results for the quarter ended 30 Sep, 2013

PART I	Sr. No	Particulars	STANDALONE										CONSOLIDATED									
			Rs. In Lacs (Except for per share data)										Rs. In Lacs (Except for per share data)									
			Quarter Ended					Six Month Ended					Quarter Ended					Half Year Ended				
			9/30/2013 (Unaudited)	6/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)	9/30/2013 (Unaudited)	9/30/2012 (Unaudited)
1		Income from Operations																				
		a) Net Sales / Income from operations (Net of Excise Duty)	5,850.08	4,164.25	3,853.01	10,014.32	7,006.27	16,527.07	6,728.18	4,226.15	10,954.32	7,671.13	17,448.10									
		b) Other Operating Income	28.00	5.93	12.76	33.94	29.18	38.68	32.79	9.13	41.93	35.05	25.36									
		Total Income from Operations (net)	5,878.08	4,170.18	3,865.77	10,048.26	7,035.45	16,565.75	6,760.97	4,235.28	10,996.25	7,706.18	17,473.46									
1		Expenses																				
		a) Cost of materials consumed	4,217.38	2,926.65	2,902.70	7,144.03	4,270.28	11,802.29	5,197.75	3,124.34	8,322.09	4,885.63	11,969.84									
		b) Purchase of stock in trade	-	-	-	-	495.21	-	-	-	-	495.21	-									
		c) Changes in inventories of finished goods and work in progress	-283.73	-282.45	-235.32	-566.18	-184.79	312.42	-583.23	-456.90	-1,040.13	-313.46	312.41									
		d) Employee benefits expenses	243.70	216.21	190.09	459.91	349.96	829.46	289.78	253.37	718.39	413.46	909.86									
		e) Depreciation and amortisation expenses	361.82	354.17	308.53	715.99	542.16	1,173.21	363.02	355.37	300.78	544.66	1,187.42									
		f) Other expenditure	607.71	453.91	436.30	1,061.62	755.87	559.51	684.26	489.55	1,173.81	827.06	1,354.68									
		Total Expenses	5,146.88	3,668.50	3,602.30	8,815.38	6,228.70	14,676.89	5,951.58	3,765.74	4,105.64	6,852.57	15,734.21									
		Profit / (Loss) from operations before other income, Finance Cost and Exceptional Items (1-2)	731.21	501.68	263.46	1,232.89	806.75	1,888.86	809.40	469.54	1,778.94	853.61	1,739.25									
3		Other Income	-	15.91	58.70	16.91	105.63	(85.26)	-	16.91	43.44	90.37	105.72									
5		Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	731.21	518.59	322.16	1,249.79	912.38	1,803.60	809.40	486.45	1,795.84	943.98	1,844.97									
6		Finance Costs	230.87	157.76	183.04	388.63	372.74	703.22	268.78	181.74	193.95	411.00	748.49									
6A		Foreign Exchange Fluctuation (Profit) / Loss	101.72	66.93	(231.28)	168.65	29.65	130.88	101.72	66.93	168.65	29.65	130.87									
7		Profit after finance costs but before Exceptional Items (5-6A)	398.62	293.90	370.40	692.52	509.98	969.50	438.90	237.78	402.23	503.33	965.61									
8		Exceptional Items (includes adjustment relating to previous year)	2.78	31.73	18.74	34.51	21.61	94.92	2.78	31.73	18.74	21.61	94.93									
9		Profit / (Loss) from ordinary activities before tax (7+8)	395.84	262.17	351.66	658.01	488.37	874.57	436.12	206.05	383.49	481.72	870.69									
10		Tax Expense	90.08	59.44	87.99	149.52	149.19	280.12	90.16	59.52	103.19	152.45	279.40									
11		Net Profit / (Loss) from ordinary activities after tax (9-10)	305.76	202.73	263.67	508.49	339.18	594.45	345.96	146.53	280.30	329.27	591.29									
12.00		Extra ordinary items	-	-	-	-	-	-	-	-	-	-	-									
13		Net Profit / (Loss) for the period (11 - 12)	305.76	202.73	263.67	508.49	339.18	594.45	345.96	146.53	280.30	329.27	591.29									
14		Share of Profit / (Loss) of associates	-	-	-	-	-	-	-	-	-	-	-									
15		Minority Interest	-	-	-	-	-	-	-	-	-	-	-									
16		Net Profit / (Loss) after taxes, minority interest and share of profit / (Loss) of associates (13-14-15)	305.76	202.73	263.67	508.49	339.18	594.45	345.96	146.53	280.30	329.27	591.29									
17		Paid-up equity share capital (Face Value Rs.10/-)	1,852.91	1,804.41	1,692.91	1,852.91	1,692.91	1,804.41	1,852.91	1,692.91	1,804.41	1,852.91	1,804.41									
18		Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	9,477.00	9,054.84	8,486.53	9,477.00	8,486.53	8,852.11	9,336.56	8,875.46	9,336.56	8,364.52	8,728.97									
19		Earnings per share - Basic	1.69	1.12	1.56	2.81	2.00	3.45	1.91	0.81	2.66	1.94	3.45									
20		Earnings per share - Diluted	1.69	1.12	1.56	2.81	2.00	3.43	1.91	0.81	2.66	1.94	3.43									



PART II									
A PARTICULARS OF SHAREHOLDING									
1.00	Public shareholding								
	- No of shares	7,772,150	7,772,150	7,497,150	7,772,150	7,772,150	7,772,150	7,497,150	7,772,150
	- Percentage of shareholding	41.95%	43.07%	44.29%	43.07%	41.95%	41.95%	44.29%	43.07%
2.00	Promoters and promoter group shareholding								
	a) Pledged / Encumbered								
	- No of shares								
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	b) Non-encumbered								
	- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	- No of shares	10,756,980	10,271,980	9,431,980	10,756,980	10,271,980	10,756,980	9,431,980	10,271,980
	- Percentage of shares (as a % of the total shareholding of promoters and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	58.05%	56.93%	55.71%	58.05%	56.93%	58.05%	55.71%	56.93%
8	PARTICULARS								
	INVESTOR COMPLAINTS								
	Pending at the beginning of the quarter	0	0	0	1				
	Received during the quarter	0	1	0	0				
	Disposed of during the quarter	0	1	1	1				
	Remaining unresolved at the end of the quarter	0	0	0	0				

- 1.00 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting on 23.10.2013
- 2.00 The company has only one reportable segment i.e. Agrochemicals & Pharma Intermediates.
- 3.00 Above Financial Results includes financials results of M/s Behram Chemicals Pvt. Ltd. (65.63% subsidiary), and Astec CropCare Pvt Ltd (100% Subsidiary of Astec), Financials of Astec Europe SpA (50.10% subsidiary) and Comercializadora Agrícola Agrostarchem Cia Ltda at Columbia (100% Subsidiary of Astec) have not been included in consolidation as there was no commercial activity during this period.
- 4.00 Figures of the previous period have been regrouped/rearranged, wherever necessary.
- 5.00 Key standalone financial information of the company is given below :-

Particulars	Quarter Ended 9/30/2013 (Un audited)	Quarter Ended 6/30/2013 (Un audited)	Quarter Ended 9/30/2012 (Un audited)	Half Year Ended 30/09/2013 (Un audited)	Half Year Ended 30/09/2012 (Un audited)	Year ended 3/31/2013 (Audited)
Net Sales / Income from operations (Net of Excise Duty)	5,850.08	4,164.25	3,853.01	7,006.27	16,527.07	
Other Operating Income	28.00	5.93	12.76	33.94	29.18	38.68
Profit / (Loss) from ordinary activities before tax	395.84	262.17	351.66	658.01	488.38	874.57
Net Profit / (Loss) from ordinary activities after tax	305.76	202.73	263.67	508.49	339.18	594.45
Earnings per share - Basic	1.69	1.12	1.56	2.74	2.00	3.45
Earnings per share - Diluted	1.69	1.12	1.42	2.74	1.83	3.43

For Astec LifeSciences Limited




(Ashok V Hiremath)
Chairman & Managing Director
Mumbai, October 23, 2013

STATEMENT OF ASSETS AND LIABILITIES
Astec Lifesciences Limited
Balance sheet as at 30 Sep 2013

	Notes	As at 9/30/2013	Standalone As at 9/30/2012	As at 3/31/2013	As at 9/30/2013	Consolidated As at 9/30/2012	As at 3/31/2013
Equity and liabilities							
Shareholders' funds							
Share capital	4	185,291,300	169,291,300	180,441,300	185,291,300	169,291,300	180,441,300
Reserves and surplus	5	947,700,160	848,653,588	885,211,568	933,656,239	836,452,702	872,897,659
Money received against share warrants			13,600,000	4,122,500	-	13,600,000	4,122,500
		1,132,991,460	1,031,544,888	1,069,775,368	1,118,947,539	1,019,344,002	1,057,461,459
Minority Interest					1,306,048	1,891,691	1,250,786
Non-current liabilities							
Long-term borrowings	6	253,504,801	170,939,157	214,554,922	258,504,801	175,939,157	214,554,922
Deferred tax liabilities (net)	7	40,359,505	31,111,917	38,567,241	35,871,943	31,375,073	38,879,127
Other long term liabilities	8	351,155,314	308,209,229	263,571,659	355,708,723	310,897,638	263,571,659
Long-term provisions	9	11,315,590	16,333,296	4,289,463	11,303,534	16,333,296	11,943,316
		656,335,212	526,593,599	520,983,285	661,389,003	534,545,164	528,949,024
Current liabilities							
Short-term borrowings	6	470,832,239	584,577,010	445,120,418	575,239,793	617,141,938	471,458,976
Trade payables	10	509,339,113	447,395,595	454,665,330	612,710,892	490,539,156	460,871,651
Other current liabilities	11	23,478,499	17,503,747	59,612,331	25,042,469	19,984,546	62,874,697
Short-term provisions	9	6,500,236	9,837,729	27,900,011	13,540,093	15,576,165	27,940,011
		1,010,150,087	1,059,314,081	987,298,090	1,226,533,247	1,143,241,805	1,023,145,335
Total		2,799,476,759	2,617,452,568	2,578,056,743	3,008,175,836	2,699,022,662	2,610,806,604
Assets							
Non-current assets							
Fixed assets							
Tangible assets	12	1,217,216,108	1,080,540,326	1,201,562,467	1,222,588,989	1,085,164,734	1,205,887,918
Intangible assets	13	616,596	303,938	437,973	1,348,718	2,173,561	1,370,094
Capital work-in-progress		160,204,383	184,711,046	130,716,146	160,204,383	184,711,046	130,716,146
Non-current investments	14	10,190,595	9,881,395	9,981,395	597,000	117,800	792,800
Deferred Tax					-	5,202,828	-
Long-term loans and advances	15	-	50,707,798	78,740,472	1,012,026	51,719,824	86,377,649
Other non-current assets	16						
		1,388,227,682	1,326,144,503	1,421,438,453	1,385,951,117	1,329,089,794	1,425,144,607
Current assets							
Current investments	17	-	159,695,491	242,800	700,000	160,395,491	242,800
Inventories	18	567,692,451	518,396,779	441,124,991	680,383,825	575,509,643	506,563,437
Trade receivables	19	594,587,703	443,920,243	601,354,109	684,668,911	504,278,727	626,497,001
Cash and bank balances	20	27,878,396	50,041,062	43,024,209	33,452,093	54,952,049	51,419,317
Short-term loans and advances	15	221,090,526	119,254,490	70,872,181	223,019,890	74,796,958	939,442
		1,411,249,076	1,291,308,065	1,156,618,290	1,622,224,719	1,369,932,868	1,185,661,997
Total		2,799,476,759	2,617,452,568	2,578,056,743	3,008,175,836	2,699,022,662	2,610,806,604

For Astec LifeSciences Limited


(Ashok V. Hiremath)
Chairman & Managing Director
Mumbai, October 23, 2013



C. A. P.M. KATHARIYA

B.Com., LLB., (Gen.), FCA

C. A. HEMANT S. MAHAVAR

B.Com., FCA

C.A. RONAK N. DHARNIDHARKA

B.Com., ACA

C.A. PRATIK M. CHOUDHARY

B.Com., ACA



SHAH & KATHARIYA
CHARTERED ACCOUNTANT

Room No. 6, Kermani Building, 4th Floor.
27, Sir P. M. Road, Fort, Mumbai - 400 001
Ph. : 6631 5862 Fax : 2285 6615 R. : 2872 8803
Mobile : 98210 34665 / 99872 49694 / 705
E-mail : admin@shahkathariya.com
Web : www.shahkathariya.com

LIMITED REVIEW REPORT


The Board of Directors of **Astec LifeSciences Limited**

1. We have reviewed the accompanying Statements of Un-audited Financial Results of Astec LifeSciences Limited (the 'Company') for the quarter ended September 30, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited or reviewed by us. These Statements are the responsibility of the Company's management and have been approved by the Board of Directors. Our responsibility is to issue a report on the Statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements of Un-audited Financial Results, prepared in accordance with applicable Accounting Standards notified pursuant to Companies (Accounting Standards) Rules, 2006 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed or that it contains any material misstatement.

For **Shah & Kathariya**

Chartered Accountants

Firm Registration No: 115171W



per **Ronak Dharnidharka**

Partner

Membership No: 141555



Place: Mumbai

Date: 23rd October, 2013